JP2019536767A - エピカテキン及び抗癌化合物の組合せを含む組成物 - Google Patents
エピカテキン及び抗癌化合物の組合せを含む組成物 Download PDFInfo
- Publication number
- JP2019536767A JP2019536767A JP2019523821A JP2019523821A JP2019536767A JP 2019536767 A JP2019536767 A JP 2019536767A JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019536767 A JP2019536767 A JP 2019536767A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- epicatechin
- combination
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Description
1.本発明の組合せは、新規であり、副作用が減少し、効力が増加する。
2.本発明の組合せは、安定であり、相乗効果を有する。
免疫無防備のマウスにおける癌異種移植モデルに対して、PI3K/mTOR阻害薬と組合せたエピカテキンの抗癌能力を評価する。CD1ヌードマウスに、ビヒクルコントロール、PI3K/mTOR阻害薬、及びPI3K/mTOR阻害薬とエピカテキンの組合せを21日間投与する。群(G−3)で腫瘍体積の減少が最大であることが見出される。群(G−3)は、組合せて投与することで97%の腫瘍増殖阻害%(TGI%)を有した。その結果を、表2、表3、図1a及び図1bに示す。
2.1 細胞培養:
正常肺細胞に対応するHell−299細胞株を正常細胞コントロールとして用いる。肺腺癌に対応するA549細胞株を37℃で5%CO2下、標準条件下で培養する。細胞を、異なる濃度のシスプラチン[CDDP(シス−ジアンミンジクロロ白金(II),Sigma)][1〜100μM]、又は(−)−エピカテキン(EC,Sigma)[0.1〜1000μM]、又は両化合物の組合せで、48時間、処理する。両方の化合物はDMSO(0.9%)に溶解される。
細胞生存率はMTTアッセイで決定される。簡単に説明すると、細胞を0.1mg/mlのMTT(3−(4,5−ジメチル−2−チアゾリル)−2,5−ジフェニルテトラゾリウム ブロマイド)と共に37℃で40分間インキュベートする。紫色のホルマザンを0.01MのHCl−イソプロパノールを用いて可溶化する。溶解した物質を595nmで分光光度的に測定する(BioteckSynergy HT)。
生存率:
(実験群の光学密度)/(コントロール群の光学密度)×100
EC及びCDDPの濃度反応曲線を決定した後、アイソボログラム解析を実施する。この方法は、最初に服用組合せの理論的分析効果を可能にし、Tallaridaによって報告された研究に基づいており、これは任意の2つの薬物間の相互作用の種類を定量的及びグラフ的に評価する。簡潔には、各化合物の阻害濃度(IC)が計算された後、式(式(1))に従って、一定の比率1:1の組合せの理論値(例えば、IC50、IC30及びIC15)を得る。次いで、それらは実験値によって置換される(式(2))。
式(1):
(CDDP理論値/ICx)+(EC理論値/ICx)=1
式(2):
(CDDP実験値/IC30)+(EC実験値/IC30)=計算結果
アポトーシスの存在は、アクリジンオレンジ/臭化エチジウム染色[15mM/0.002mM]を用いて評価される。アクリジンオレンジ(AO)は細胞核を緑色に染める。エチジウムブロマイド(EB)は、原形質膜の完全性が失われた場合にのみ細胞核を赤色に染色する。画像取得のために落射蛍光顕微鏡(Nikon Elipse E600)を用いる。生存し健全な細胞は、光沢のある緑色の染色を呈する。アポトーシス過程にある細胞及び死細胞は、光沢のある赤色の染色を示す。
γ=(IC30実験値/IC30理論値)=0.741/2.96=0.250
γ=1 相加作用
γ<1 相乗作用
γ>1 拮抗作用
図3から、NCI−H1299及びHCC−827等の肺癌細胞株に基づく細胞障害性モデルにおいて、本発明の(−)−エピカテキンとシスプラチンの組合せが、相乗的であることが認められる。
Claims (13)
- エピカテキンと少なくとも1つの抗癌化合物の新規な組合せ。
- 前記エピカテキンが、(+)−エピカテキン、(−)−エピカテキン、及び(+)−エピカテキンと(−)−エピカテキンの混合物を含む群から選択される、請求項1に記載の組合せ。
- (+)−エピカテキン:(−)−エピカテキンの比率が0.1:99.9〜99.9:0.1の範囲内である、請求項1に記載の組合せ。
- エピカテキン:抗癌化合物の比率が、0.1:99.9〜99.9:0.1の範囲内である、請求項1に記載の組合せ。
- 前記抗癌化合物が、シクロホスファミド、ニトソウレア、アルコールスルホネート等のアルキル化抗腫瘍化合物;シスプラチン、カルボプラチン、オキサリプラチン等の白金配位化合物;メトトレキサート、6−メルカプトプリン、5−フルオロウラシル(5−FU)、ゲムシタビン等の代謝拮抗薬;ドキソルビシン等の抗腫瘍抗薬;ドセタキセル、パクリタキセル、トポテカン、エトポシド、イリノテカン、ビンブラスチン等の微小管阻害薬;イマチニブ、ラパチニブ、スニチニブ、ソラフェニブ、テムシロリムス等の生物学的化合物;イバンドロン酸、ゾレドロン酸等のビスホスホネート;免疫療法化合物;標的抗癌療法化合物;選択的又は非選択的なPI3キナーゼ阻害薬、mTOR阻害薬、MEK阻害薬、Akt阻害薬、EGF受容体を標的とするイマチニブ、エルロチニブ、ゲフィチニブ等のチロシンキナーゼ阻害薬;FGF、VEGF、PDGFに対するスニチニブ阻害薬;ALK阻害薬、ABL阻害薬、SCR阻害薬、FLT3阻害薬、KIT阻害薬、MET阻害薬、BRAF阻害薬、Ilβ阻害薬、JAK1/2阻害薬、JAK3阻害薬、プロテオソーム阻害薬ボルテゾミブ、他の成長因子阻害薬、RAS/RAF/MAPK経路の阻害薬、他のシグナル伝達阻害薬、多標的キナーゼ阻害薬、トポイソメラーゼ阻害薬、解糖系阻害薬、カテプシンB阻害薬、ヒストン脱アセチル化酵素阻害薬等の群から選択される他の一般的な免疫療法化合物等を含む群から選択され、単独又は他の抗癌化合物と組合せて用いられ、好ましくは抗癌化合物がシスプラチン、カルボプラチン又はオキサリプラチン等の白金含有抗癌剤、PI3キナーゼ/mTOR阻害薬等の化学療法化合物を含む群から選択される、請求項1に記載の組合せ。
- PI3キナーゼ/mTORを有する抗癌化合物が、以下の化合物を含む群から選択される、請求項1及び5に記載の組合せ:
i.4−(4−(2−アミノチアゾール−5−イル)−6−モルホリノ−1,3,5−トリアジン−2−イルオキシ)−N,N−ジメチルベンズアミド;
ii.4−(4−(2−アミノチアゾール−5−イル)−6−モルホリノ−1,3,5−トリアジン−2−イルオキシ)−N,N−ジメチルベンズアミド;
iii.(S)−4−((4−(2−アミノチアゾール−5−イル)−6−(3−メチルモルホリノ)−1,3,5−トリアジン−2−イル)オキシ)−3−フルオロ−N,N−ジメチルベンズアミド;
iv.(S)−4−((4−(6−アミノピリジン−3−イル)−6−(3−メチルモルホリノ)−1,3,5−トリアジン−2−イル)オキシ)−3−フルオロ−N,N−ジメチルベンズアミド。 - PI3キナーゼ/mTORを有する抗癌化合物が、以下の化合物を含む群から選択される、請求項1及び5に記載の組合せ:
- 請求項1に記載の組合せを、他の薬学的許容される賦形剤と共に含む新規な組成物。
- 癌治療で相乗効果をもたらすための、請求項1に記載の新規な組合せの使用。
- 抗癌組合せに対する患者の耐性の発症リスクを減少させるための、請求項1に記載の新規な組合せの使用。
- 肥満に関連する効果を減少させるための、請求項1に記載の新規な組合せの使用。
- 癌細胞に対する免疫応答を誘導するための、請求項1に記載の新規な組合せの使用。
- ワールブルク効果を減少させるための、請求項1に記載の新規な組合せの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611037375 | 2016-11-01 | ||
IN201611037375 | 2016-11-01 | ||
PCT/IN2017/050506 WO2018083713A1 (en) | 2016-11-01 | 2017-11-01 | Composition comprising combination of epicatechin and anti-cancer compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019536767A true JP2019536767A (ja) | 2019-12-19 |
JP2019536767A5 JP2019536767A5 (ja) | 2020-12-03 |
Family
ID=62076542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019523821A Pending JP2019536767A (ja) | 2016-11-01 | 2017-11-01 | エピカテキン及び抗癌化合物の組合せを含む組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190262347A1 (ja) |
EP (1) | EP3535252A4 (ja) |
JP (1) | JP2019536767A (ja) |
CN (1) | CN110312709A (ja) |
WO (1) | WO2018083713A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021162126A1 (ja) * | 2020-02-13 | 2021-08-19 | シーシーアイホールディングス株式会社 | 腫瘍細胞におけるアスパラギン酸合成の阻害剤、腫瘍細胞のスフェロイド形成阻害剤、腫瘍細胞の転移抑制剤、解糖系阻害剤の作用増強剤、並びに腫瘍の転移の抑制および/または予防用医薬組成物 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170430A1 (en) | 2011-06-06 | 2012-12-13 | Cardero Therapeutics, Inc. | Methods and compositions for treatment of mitochondrial toxicity |
US20180193306A1 (en) | 2012-03-23 | 2018-07-12 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders and bone disorders |
WO2016013030A2 (en) | 2014-07-23 | 2016-01-28 | Sphaera Pharma Pvt. Ltd. | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof |
US10898465B2 (en) | 2016-06-21 | 2021-01-26 | Epirium Bio Inc. | Utility of (+) epicatechin and their analogs |
US20210380535A1 (en) | 2018-10-24 | 2021-12-09 | Epirium Bio Inc. | Co-crystals comprising epicatechin and a carboxy-n-heterocyclic co-crystal former |
CN115025236B (zh) * | 2022-05-09 | 2024-03-08 | 聊城大学 | 一种加载化疗药物-茶多酚联合药物的pH响应型靶向DNA纳米载药体系 |
WO2024036225A1 (en) | 2022-08-10 | 2024-02-15 | Epirium Bio Inc. | Epicatechin for inhibiting glutamate toxicity |
WO2024036223A1 (en) | 2022-08-10 | 2024-02-15 | Epirium Bio Inc. | Epicatechin inhibiting atp hydrolysis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070054868A1 (en) * | 2005-06-20 | 2007-03-08 | The Trustees Of Columbia University In The City Of New York | Synergistic polyphenol compounds, compositions thereof, and uses thereof |
JP2011105763A (ja) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
JP2015526424A (ja) * | 2012-07-23 | 2015-09-10 | スファエラ ファーマ ピーティーイー リミテッド | 新規トリアジン化合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192612B2 (en) * | 2001-02-22 | 2007-03-20 | Purdue Research Foundation | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
-
2017
- 2017-11-01 WO PCT/IN2017/050506 patent/WO2018083713A1/en unknown
- 2017-11-01 CN CN201780081834.1A patent/CN110312709A/zh active Pending
- 2017-11-01 US US16/345,790 patent/US20190262347A1/en not_active Abandoned
- 2017-11-01 EP EP17867283.8A patent/EP3535252A4/en not_active Withdrawn
- 2017-11-01 JP JP2019523821A patent/JP2019536767A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011105763A (ja) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
US20070054868A1 (en) * | 2005-06-20 | 2007-03-08 | The Trustees Of Columbia University In The City Of New York | Synergistic polyphenol compounds, compositions thereof, and uses thereof |
JP2015526424A (ja) * | 2012-07-23 | 2015-09-10 | スファエラ ファーマ ピーティーイー リミテッド | 新規トリアジン化合物 |
Non-Patent Citations (3)
Title |
---|
AM.J.PHYSIOL.RENAL PHYSIOL., vol. 303, JPN6021030799, 2012, pages 1264 - 1274, ISSN: 0004567188 * |
ANTICANCER RESEARCH, vol. 32, JPN6021030797, 2012, pages 2905 - 2913, ISSN: 0004567186 * |
PLOS ONE, vol. 9, JPN6021030798, 2014, pages 88322, ISSN: 0004567187 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021162126A1 (ja) * | 2020-02-13 | 2021-08-19 | シーシーアイホールディングス株式会社 | 腫瘍細胞におけるアスパラギン酸合成の阻害剤、腫瘍細胞のスフェロイド形成阻害剤、腫瘍細胞の転移抑制剤、解糖系阻害剤の作用増強剤、並びに腫瘍の転移の抑制および/または予防用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP3535252A1 (en) | 2019-09-11 |
CN110312709A (zh) | 2019-10-08 |
WO2018083713A1 (en) | 2018-05-11 |
EP3535252A4 (en) | 2020-06-17 |
US20190262347A1 (en) | 2019-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019536767A (ja) | エピカテキン及び抗癌化合物の組合せを含む組成物 | |
Rosilio et al. | Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia | |
Bayati et al. | Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells | |
JP5785157B2 (ja) | Plk1阻害剤および抗腫瘍剤を含む治療組合せ | |
RU2013148732A (ru) | Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения | |
Winegarden et al. | A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer | |
EP3027191A1 (en) | Combinations of a btk inhibitor and fluorouracil for treating cancers | |
CN111902147A (zh) | 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗 | |
AU2017254774A1 (en) | Chemotherapy improvements | |
Folkvord et al. | Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? | |
KR20190056758A (ko) | 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법 | |
US20230158042A1 (en) | Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent | |
JP5694782B2 (ja) | 肺癌、腺癌及び他の病状のための治療方法及び組成物 | |
CN110740751A (zh) | 用于治疗肺癌的结合物 | |
EP2996773A2 (en) | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents | |
AU2013233094A1 (en) | Novel antitumor agent comprising combination of three agents | |
JP2023536389A (ja) | ペンタアザ大環状環複合体およびホルモン療法剤の併用がん治療法 | |
CA2831208A1 (en) | Method of treating prostate cancer | |
US20220168319A1 (en) | COMBINED USE OF A-NOR-5alpha ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG | |
RU2763544C2 (ru) | Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции | |
CN111643502A (zh) | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 | |
TW201800091A (zh) | 包含奎寧鹽懸浮液的用於抗癌治療的局部給藥用注射劑組合物 | |
Seminara et al. | Mitomycin C and Etoposide in Advanced Colorectal Carcinoma: A Clinical and in vitro Experience That Focuses the Problem of Schedule Dependence in Combination Therapy | |
WO2024026273A1 (en) | Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex | |
WO2016046316A1 (en) | Antitumor activity of multi-kinase inhibitors in colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201021 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201021 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210810 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220308 |